Figure S2. Heat maps of Bliss synergy scores across the combination dose-response matrices for all twenty-six cell lines grown as multicellular complex spheroids exposed to each DNA damaging agent (A, TMZ; B, topotecan; C, trabectedin) in combination with PARP inhibitors, olaparib or talazoparib.</p
Figure S2. (A) LNCaP, PC-3, CWR22Rv1 and C4–2 cells were treated with SAHA and veliparib alone or in...
Figure S3. Effect of combinations of olaparib and ionizing radiation on the formation of γH2AX and 5...
Figure S1. Effect of combinations of olaparib and ionizing radiation on the formation of γH2AX and 5...
Figure S3. Heat maps of Bliss synergy scores across the combination dose-response matrices for all t...
Figure S5. Heat maps of Bliss synergy scores across the combination dose-response matrices for all t...
Figure S4. Heat maps of Bliss synergy scores across the combination dose-response matrices for all t...
Figure S1. Representative brightfield images for assay optimized cell densities from a DMSO-treated...
Figure S2. Effect of combinations of olaparib and ionizing radiation on the formation of γH2AX and 5...
Summary: Chemotherapy is used to treat most cancer patients, yet our understanding of factors that d...
RT2 ProfilerTM PCR Array Human p53 Signaling Pathway and Human DNA Repair Pathway</p
Figure S1. Synergistic growth-inhibition between AZD1775 and olaparib in GC cells. After GC cells we...
Validating in vitro drug synergy in in vivo combination studies. The TOP1 inhibitor irinotecan and t...
<p>The figure depicts EWS cellular response following DNA damage (DNA double-strand breaks and ROS p...
Supplementary Table S4: Targeted Lesions at Baseline. The baseline sum of targeted lesions (mm) for ...
<p>The heatmaps illustrate changes in spheroid growth (A: Area) and general symmetry (B: Roundness) ...
Figure S2. (A) LNCaP, PC-3, CWR22Rv1 and C4–2 cells were treated with SAHA and veliparib alone or in...
Figure S3. Effect of combinations of olaparib and ionizing radiation on the formation of γH2AX and 5...
Figure S1. Effect of combinations of olaparib and ionizing radiation on the formation of γH2AX and 5...
Figure S3. Heat maps of Bliss synergy scores across the combination dose-response matrices for all t...
Figure S5. Heat maps of Bliss synergy scores across the combination dose-response matrices for all t...
Figure S4. Heat maps of Bliss synergy scores across the combination dose-response matrices for all t...
Figure S1. Representative brightfield images for assay optimized cell densities from a DMSO-treated...
Figure S2. Effect of combinations of olaparib and ionizing radiation on the formation of γH2AX and 5...
Summary: Chemotherapy is used to treat most cancer patients, yet our understanding of factors that d...
RT2 ProfilerTM PCR Array Human p53 Signaling Pathway and Human DNA Repair Pathway</p
Figure S1. Synergistic growth-inhibition between AZD1775 and olaparib in GC cells. After GC cells we...
Validating in vitro drug synergy in in vivo combination studies. The TOP1 inhibitor irinotecan and t...
<p>The figure depicts EWS cellular response following DNA damage (DNA double-strand breaks and ROS p...
Supplementary Table S4: Targeted Lesions at Baseline. The baseline sum of targeted lesions (mm) for ...
<p>The heatmaps illustrate changes in spheroid growth (A: Area) and general symmetry (B: Roundness) ...
Figure S2. (A) LNCaP, PC-3, CWR22Rv1 and C4–2 cells were treated with SAHA and veliparib alone or in...
Figure S3. Effect of combinations of olaparib and ionizing radiation on the formation of γH2AX and 5...
Figure S1. Effect of combinations of olaparib and ionizing radiation on the formation of γH2AX and 5...